Pfizer (PFE)

If you are looking for dividend stocks, a good place to start is with unloved stocks like these, with yields of up to 6.4%.

Microsoft just became the second company in the world to amass $4 trillion in market capitalization, thanks to its AI businesses.

These pharmaceutical giants are well worth a second look.

Moderna beat Q2 earnings and revenue estimates, narrowed its annual forecast, won a key patent case, and plans to cut 10% of its global workforce.

President Donald Trump has issued a 60-day ultimatum to 17 major pharmaceutical companies, demanding that they lower drug prices in the U.S. or face severe consequences.

Pfizer presents a good buying opportunity, but not because of potential earnings.

The big drugmaker should be even bigger over the next five years despite facing a patent cliff.

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.

You'll often find the fattest dividend yields among stocks that have tumbled for some reason.

Pfizer, Inc. stock still looks cheap ahead of its upcoming Aug. 5 Q2 earnings release. Moreover, investors can make extra income by selling out-of-the-money (OTM) put options.

In a surprising turn of events, shares of pharmaceutical giant Novo Nordisk (NYSE:NVO) fell sharply following the company’s announcement of a significant leadership restructuring. The abrupt changes at the top echelons of the Danish drugmaker sent shockwaves through the investor community, wiping billions off its market capitalization and

The pharmaceutical industry could face a significant financial hit due to the new trade deal between the U.S. and the European Union (EU), potentially leading to increased drug prices and restricted access.

Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. is pledging a major overhaul of the National Vaccine Injury Compensation Program (VICP), describing the system as fundamentally broken and failing its intended purpose.

These big pharma stocks arguably aren't receiving the respect they deserve.

Sci-fi becomes reality: AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school giants.

AI-native players like Palantir, Tempus, and Recursion are disrupting drug discovery and attracting investors, while Big Pharma struggles.

Over the last six months, Zoetis’s shares have sunk to $153.39, producing a disappointing 11.4% loss - a stark contrast to the S&P 500’s 5.8% gain. This may have investors wondering how to approach the situation.

On CNBC's "Mad Money Lightning Round," Jim Cramer praised home improvement retailer Lowe's Companies and CrowdStrike Holdings.

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Zoetis (NYSE:ZTS) and its peers.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Bristol-Myers Squibb (NYSE:BMY) and the best and worst performers in the branded pharmaceuticals industry.

The entire healthcare sector has fallen into a deeply discounted valuation, creating opportunities for investors who hunt for value and upside

The results represent a best-case scenario for the company in treating inflammatory bowel disease, according to one analyst.